What is metabolic disease? Metabolic syndrome as one root cause of several diagnoses

"Metabolic disease" is not a single condition. It is a cluster of five related derangements that together define metabolic syndrome and ultimately produce type 2 diabetes, fatty liver, atherosclerosis and chronic fatigue. Roughly one in three Estonian adults meets the criteria — which usually means the core of metabolism, the action of insulin, has been failing quietly for years.

The five criteria clinicians actually look at

Alberti et al. (Circulation 2009, IDF/AHA harmonised definition) diagnose metabolic syndrome when at least 3 of the following 5 are present:

• Waist circumference: men ≥ 94 cm, women ≥ 80 cm
• Fasting triglycerides ≥ 1.7 mmol/L (or on therapy)
• HDL cholesterol: men < 1.0 mmol/L, women < 1.3 mmol/L
• Blood pressure ≥ 130/85 mmHg (or on therapy)
• Fasting glucose ≥ 5.6 mmol/L (or known type 2 diabetes)

Three of five is the minimum for a diagnosis. But clinically the more useful question is what sits underneath all five: hyperinsulinaemia and insulin resistance (Reaven, Diabetes 1988). Reaven showed already in 1988 that these are not five separate problems but five faces of one cause.

Why waist size is the loudest signal

Subcutaneous fat is a relatively passive energy depot. Visceral fat — the fat that accumulates around the liver, pancreas and gut inside the abdominal cavity — is an active endocrine organ that secretes inflammatory cytokines (TNF-α, IL-6), releases free fatty acids directly into the portal vein, and impairs hepatic insulin sensitivity. Waist growing without hip growing is the textbook metabolic phenotype.

Even in someone with a "normal" BMI of 22–24, a TOFI pattern (thin outside, fat inside) can hide substantial visceral fat with no weight gain. MRI and bioimpedance frequently reveal this in the "outwardly healthy" 40-something patient who presents with fatigue.

Fatty liver: quiet, but reversible

Non-alcoholic fatty liver disease (NAFLD, now MASLD) is more prevalent than type 2 diabetes worldwide — 25–30% of adults (Younossi et al., Hepatology 2019). It is often the earliest lab marker of metabolic disease, before glucose or blood pressure move: mild ALT/AST elevation and steatosis on ultrasound. Fatty liver is fully reversible when insulin sensitivity is restored.

Why losing weight alone is not enough

Weight loss is the single biggest lever, but it is not sufficient by itself. The DiRECT trial (Lean et al., Lancet 2018) showed 46% of patients entering type 2 diabetes remission with an intensive lifestyle program and 10–15 kg of weight loss — but the key was not weight per se, it was where the fat came off: visceral and hepatic depots. Losing the same weight from subcutaneous stores alone does not restore insulin sensitivity.

Three components carry roughly equal weight:

• Nutrition that lowers the insulin burden — carbohydrate quality and distribution, adequate protein (1.4–1.8 g/kg), 30+ g fiber a day
• Muscle mass and interval work — strength training 2–3× a week is the strongest single lever for restoring insulin sensitivity
• Sleep architecture and deliberate stress work — one bad night drops insulin sensitivity by ~25% the next day (Donga et al., JCEM 2010)

How to tell metabolic disease from other causes

Metabolic syndrome is diagnosed with lab values and a tape measure. But several conditions mimic it and need to be excluded: hypothyroidism, Cushing's syndrome, PCOS, certain medications (steroids, atypical antipsychotics, some antidepressants), and rare genetic lipodystrophies. Only a physician can make that distinction, based on clinical picture and targeted work-up.

Realistic timelines

In a structured 12-week program I typically see meaningful change in the first three criteria: waist −4 to −8 cm, triglycerides −20 to −40%, HDL +5 to +15%. Blood pressure and fasting glucose move more slowly — 3–6 months. HbA1c reflects 60–90 days of red-cell exposure, so measuring it before 12 weeks is not informative. Insulin and HOMA-IR move fastest — a real drop is often already visible at 6–8 weeks.

Metabolic syndrome as a marker of early mortality

Metabolic syndrome (waist + elevated TG + low HDL + elevated BP + elevated fasting glucose) increases cardiovascular mortality 2–3× and type 2 diabetes risk 5× (Mottillo et al., JACC 2010). Three of the criteria are already diagnostic — most people don't know until their first heart attack.

Early signals not to ignore

• Waist > 94 cm (male) / > 80 cm (female) even at 'normal' BMI
• Fasting triglycerides > 1.5 mmol/l
• HDL < 1.0 (male) / < 1.3 (female)
• 3–4 am awakenings + morning fatigue (cortisol-glucose axis)

Reversibility: what is proven

The DiRECT trial (Lancet 2018) showed 46% of T2D patients achieved remission with 15 kg weight loss and a structured dietary intervention. The earlier the intervention, the higher the chance of full reversal.